

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tari Leslie</u> (Last) (First) (Middle) <u>C/O CIDARATHERAPEUTICS, INC.</u> <u>6310 NANCY RIDGE DR. SUITE</u> <u>101</u> (Street) <u>SAN</u> <u>CA</u> <u>92121</u> <u>DIEGO</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/01/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>Cidara Therapeutics, Inc. [CDTX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,551	D	
Common Stock	13,298	I	By spouse

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)	09/08/2024	Common Stock	30,708	2.29	D	
Stock Option (right to buy)	(2)	12/17/2026	Common Stock	49,739	2.45	D	
Stock Option (right to buy)	(1)	12/17/2026	Common Stock	79,221	2.45	D	
Stock Option (right to buy)	(3)	03/18/2030	Common Stock	85,000	1.98	D	
Stock Option (right to buy)	(4)	03/16/2031	Common Stock	120,000	2.55	D	
Restricted Stock Unit	(5)	01/01/2022	Common Stock	3,675	(6)	D	
Stock Option (right to buy)	(1)	12/17/2026	Common Stock	918	2.45	I	By spouse
Stock Option (right to buy)	(1)	12/17/2026	Common Stock	3,927	2.45	I	By spouse
Stock Option (right to buy)	(1)	03/18/2030	Common Stock	521	1.98	I	By spouse
Stock Option (right to buy)	(1)	03/16/2031	Common Stock	104	2.55	I	By spouse

Explanation of Responses:

1. Shares are fully vested

2. One-third (1/3) of the shares subject to the option vested on December 18, 2020 and the remainder vests and becomes exercisable in a series of twenty-four (24) successive equal monthly installments thereafter until fully vested on December 18, 2022.

3. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020.

4. The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.

5. The shares shall vest upon the achievement of various clinical and corporate milestones.

6. Restricted stock units convert into common stock on a one-for-one basis.

Remarks:

/s/ Leslie Tari

07/06/2021

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.